🚀 VC round data is live in beta, check it out!
Generation Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Generation Bio and similar public comparables like Outlook Therapeutics, FibroGen, Pluri, Mabion and more.
Generation Bio Overview
About Generation Bio
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Founded
2016
HQ
Employees
115
Website
Financials (LTM)
Market Cap
$36M
Generation Bio Financials
Generation Bio reported last 12-month revenue of $9M.
In the same LTM period, Generation Bio generated had net loss of ($69M).
Revenue (LTM)
Generation Bio P&L
In the most recent fiscal year, Generation Bio reported revenue of — and net income of —.
Generation Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $9M | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (796%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($69M) | XXX | — | XXX | XXX | XXX |
| Net Margin | (753%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Generation Bio Stock Performance
Generation Bio has current market cap of $36M.
Generation Bio's stock price is $5.34.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $36M | 0.0% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGeneration Bio Valuation Multiples
Generation Bio trades at (3.0x) EV/Revenue multiple.
Generation Bio Financial Valuation Multiples
As of March 21, 2026, Generation Bio has market cap of $36M.
Equity research analysts estimate Generation Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Generation Bio has a P/E ratio of (0.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $36M | XXX | $36M | XXX | XXX | XXX |
| EV (current) | ($28M) | XXX | ($28M) | XXX | XXX | XXX |
| EV/Revenue | (3.0x) | XXX | — | XXX | XXX | XXX |
| EV/EBIT | 0.4x | XXX | — | XXX | XXX | XXX |
| P/E | (0.5x) | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Generation Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Generation Bio Margins & Growth Rates
Generation Bio's revenue in the last 12 month declined by (100%).
Generation Bio's revenue per employee in the last FY averaged $0.1M.
Generation Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (100%) | XXX | (41%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Generation Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Outlook Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| FibroGen | XXX | XXX | XXX | XXX | XXX | XXX |
| Pluri | XXX | XXX | XXX | XXX | XXX | XXX |
| Mabion | XXX | XXX | XXX | XXX | XXX | XXX |
| Jiangsu Wuzhong Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Generation Bio M&A Activity
Generation Bio acquired XXX companies to date.
Last acquisition by Generation Bio was on XXXXXXXX, XXXXX. Generation Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Generation Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGeneration Bio Investment Activity
Generation Bio invested in XXX companies to date.
Generation Bio made its latest investment on XXXXXXXX, XXXXX. Generation Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Generation Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Generation Bio
| When was Generation Bio founded? | Generation Bio was founded in 2016. |
| Where is Generation Bio headquartered? | Generation Bio is headquartered in United States. |
| How many employees does Generation Bio have? | As of today, Generation Bio has over 115 employees. |
| Is Generation Bio publicly listed? | Yes, Generation Bio is a public company listed on Nasdaq. |
| What is the stock symbol of Generation Bio? | Generation Bio trades under GBIO ticker. |
| When did Generation Bio go public? | Generation Bio went public in 2020. |
| Who are competitors of Generation Bio? | Generation Bio main competitors are Outlook Therapeutics, FibroGen, Pluri, Mabion. |
| What is the current market cap of Generation Bio? | Generation Bio's current market cap is $36M. |
| What is the current revenue of Generation Bio? | Generation Bio's last 12 months revenue is $9M. |
| What is the current revenue growth of Generation Bio? | Generation Bio revenue growth (NTM/LTM) is (100%). |
| What is the current EV/Revenue multiple of Generation Bio? | Current revenue multiple of Generation Bio is (3.0x). |
| Is Generation Bio profitable? | No, Generation Bio is not profitable. |
| What is the current net income of Generation Bio? | Generation Bio's last 12 months net income is ($69M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.